JP2016517432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517432A5 JP2016517432A5 JP2016502769A JP2016502769A JP2016517432A5 JP 2016517432 A5 JP2016517432 A5 JP 2016517432A5 JP 2016502769 A JP2016502769 A JP 2016502769A JP 2016502769 A JP2016502769 A JP 2016502769A JP 2016517432 A5 JP2016517432 A5 JP 2016517432A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- membered
- phenyl
- membered heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(CCC(C)C)C*C(C1CCC(*N)CC1)=C Chemical compound CCC(CCC(C)C)C*C(C1CCC(*N)CC1)=C 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790637P | 2013-03-15 | 2013-03-15 | |
| US61/790,637 | 2013-03-15 | ||
| US201361914915P | 2013-12-11 | 2013-12-11 | |
| US61/914,915 | 2013-12-11 | ||
| PCT/US2014/028370 WO2014144100A2 (en) | 2013-03-15 | 2014-03-14 | Sgc stimulators |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080300A Division JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080301A Division JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Division JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517432A JP2016517432A (ja) | 2016-06-16 |
| JP2016517432A5 true JP2016517432A5 (enExample) | 2017-04-20 |
Family
ID=50513493
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502769A Pending JP2016517432A (ja) | 2013-03-15 | 2014-03-14 | ｓＧＣ刺激薬 |
| JP2017080301A Active JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080300A Active JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Active JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
| JP2020081703A Active JP7072602B2 (ja) | 2013-03-15 | 2020-05-07 | ｓＧＣ刺激薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080301A Active JP6267385B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2017080300A Active JP6267384B2 (ja) | 2013-03-15 | 2017-04-14 | ｓＧＣ刺激薬 |
| JP2018193191A Active JP6709000B2 (ja) | 2013-03-15 | 2018-10-12 | ｓＧＣ刺激薬 |
| JP2020081703A Active JP7072602B2 (ja) | 2013-03-15 | 2020-05-07 | ｓＧＣ刺激薬 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US9481689B2 (enExample) |
| EP (3) | EP3998260B1 (enExample) |
| JP (5) | JP2016517432A (enExample) |
| KR (3) | KR102218771B1 (enExample) |
| CN (5) | CN110016020B (enExample) |
| AU (4) | AU2014227862C1 (enExample) |
| BR (1) | BR112015023349A2 (enExample) |
| CA (1) | CA2907111C (enExample) |
| CY (2) | CY1122919T1 (enExample) |
| DK (2) | DK2970243T3 (enExample) |
| EA (2) | EA033168B1 (enExample) |
| ES (3) | ES2911276T3 (enExample) |
| HR (2) | HRP20200276T1 (enExample) |
| HU (2) | HUE048543T2 (enExample) |
| IL (4) | IL285564B2 (enExample) |
| LT (2) | LT2970243T (enExample) |
| ME (1) | ME03664B (enExample) |
| MX (3) | MX384408B (enExample) |
| PL (2) | PL3660013T3 (enExample) |
| PT (2) | PT3660013T (enExample) |
| RS (2) | RS63108B1 (enExample) |
| SI (2) | SI3660013T1 (enExample) |
| WO (1) | WO2014144100A2 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002360765C1 (en) | 2001-12-20 | 2009-06-11 | Trivascular, Inc. | Advanced endovascular graft |
| CA3035048C (en) | 2010-12-23 | 2021-05-04 | Mark Deem | System for mitral valve repair and replacement |
| AU2012272855C1 (en) | 2011-06-21 | 2018-04-05 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| AU2012325809B2 (en) | 2011-10-19 | 2016-01-21 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
| US9763780B2 (en) | 2011-10-19 | 2017-09-19 | Twelve, Inc. | Devices, systems and methods for heart valve replacement |
| US9655722B2 (en) | 2011-10-19 | 2017-05-23 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US11202704B2 (en) | 2011-10-19 | 2021-12-21 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| US9039757B2 (en) | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| CA2849030C (en) | 2011-10-19 | 2020-10-27 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
| CA2861804C (en) * | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| EP2897953B8 (en) | 2012-09-19 | 2019-06-26 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| WO2014189974A1 (en) | 2013-05-20 | 2014-11-27 | Twelve, Inc. | Implantable heart valve devices, mitral valve repair devices and associated systems and methods |
| JP2016540017A (ja) * | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激物質 |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| EP3194382B1 (en) | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| WO2016044445A2 (en) * | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| CN107223125B (zh) * | 2014-09-17 | 2019-09-27 | 赛科理音医疗有限公司 | sGC刺激剂 |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| LT3325013T (lt) | 2015-07-23 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas |
| JP7111610B2 (ja) | 2015-08-21 | 2022-08-02 | トゥエルヴ， インコーポレイテッド | 埋込可能な心臓弁デバイス、僧帽弁修復デバイス、ならびに関連するシステム及び方法 |
| BR112018011154B1 (pt) * | 2015-11-30 | 2023-09-26 | Cyclerion Therapeutics, Inc | Dispersões sólidas compreendendo um estimulador de sgc |
| KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| WO2017122754A1 (ja) | 2016-01-12 | 2017-07-20 | 日本ケミファ株式会社 | 電位依存性ｔ型カルシウムチャネル阻害剤 |
| US11357777B2 (en) | 2016-02-01 | 2022-06-14 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| CN105753783B (zh) * | 2016-04-08 | 2017-12-15 | 李文淏 | 一种合成塞来昔布的方法 |
| EP3448316B1 (en) | 2016-04-29 | 2023-03-29 | Medtronic Vascular Inc. | Prosthetic heart valve devices with tethered anchors |
| KR102513343B1 (ko) | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| EA201990236A1 (ru) | 2016-07-07 | 2019-08-30 | Сайклерион Терапьютикс, Инк. | Новые способы получения стимуляторов растворимой гуанилатциклазы |
| EA039753B1 (ru) | 2016-07-07 | 2022-03-10 | Сайклерион Терапьютикс, Инк. | ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC |
| KR102487872B1 (ko) * | 2016-07-07 | 2023-01-12 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법 |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| EA038096B1 (ru) * | 2016-09-23 | 2021-07-06 | Сайклерион Терапьютикс, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| ES2985316T3 (es) | 2016-10-11 | 2024-11-05 | Bayer Pharma AG | Combinación que contiene el estimulador sGC vericuguat y el antagonista de los receptores de corticoides minerales finerenona |
| US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
| AU2017356887B2 (en) | 2016-11-08 | 2022-06-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| US10575950B2 (en) | 2017-04-18 | 2020-03-03 | Twelve, Inc. | Hydraulic systems for delivering prosthetic heart valve devices and associated methods |
| US10433961B2 (en) | 2017-04-18 | 2019-10-08 | Twelve, Inc. | Delivery systems with tethers for prosthetic heart valve devices and associated methods |
| US10702378B2 (en) | 2017-04-18 | 2020-07-07 | Twelve, Inc. | Prosthetic heart valve device and associated systems and methods |
| US10792151B2 (en) | 2017-05-11 | 2020-10-06 | Twelve, Inc. | Delivery systems for delivering prosthetic heart valve devices and associated methods |
| US10646338B2 (en) | 2017-06-02 | 2020-05-12 | Twelve, Inc. | Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods |
| US10709591B2 (en) | 2017-06-06 | 2020-07-14 | Twelve, Inc. | Crimping device and method for loading stents and prosthetic heart valves |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| US10729541B2 (en) | 2017-07-06 | 2020-08-04 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| US10786352B2 (en) | 2017-07-06 | 2020-09-29 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
| IL272032B2 (en) | 2017-07-17 | 2026-04-01 | Vertex Pharma | Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and |
| MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7337067B2 (ja) * | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激薬 |
| CN111902410B (zh) * | 2018-01-10 | 2024-04-19 | 赛克里翁治疗有限公司 | 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物 |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| CN108129387B (zh) * | 2018-01-31 | 2020-05-22 | 南京药石科技股份有限公司 | 一种合成2-氮杂二环[4．1．0]庚烷-1-甲酸盐酸盐的制备方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| TW202038963A (zh) * | 2018-12-05 | 2020-11-01 | 瑞士商優洛凡特科學公司 | 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途 |
| AU2019396622B2 (en) * | 2018-12-13 | 2024-11-07 | Edwards Lifesciences Corporation | Blood oxygenation treatment methods and devices |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| BR102019016950A2 (pt) * | 2019-08-15 | 2021-02-23 | Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu | forma de dosagem intrauretral de medicamento; e dispositivo |
| CN115175683A (zh) * | 2019-10-29 | 2022-10-11 | 赛克里翁治疗有限公司 | 用sGC刺激剂治疗糖尿病性肾病 |
| CA3170507A1 (en) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| WO2021172982A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
| CN111440315B (zh) * | 2020-04-28 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种自修复热塑性聚脲弹性体及其制备方法 |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
| CN112569179B (zh) * | 2020-12-25 | 2022-12-27 | 上海交通大学医学院附属第九人民医院 | 一种可注射水凝胶体系及其制备方法 |
| CN117062607A (zh) * | 2021-03-11 | 2023-11-14 | 拉堤果生物医疗股份有限公司 | 经甲基取代的吡啶和哒嗪化合物、其衍生物和其使用方法 |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| CN115932092A (zh) * | 2022-12-02 | 2023-04-07 | 中国科学院昆明植物研究所 | 玛咖产品中添加有pde-5抑制剂的检测方法与应用 |
| US20240408116A1 (en) * | 2023-06-08 | 2024-12-12 | Ilylt, Llc | Compositions for enhancing sexual pleasure with reduced pharmaceutical load of pde5 inhibitor |
| US12329775B2 (en) | 2023-08-15 | 2025-06-17 | Soundbites Public Benefit Corporation | Composition and method for treating hearing loss |
| CN117582909B (zh) * | 2024-01-19 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | 一种连续生产5-单硝酸异山梨酯的系统和方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| EP0605622B1 (en) | 1991-09-24 | 1997-11-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5571897A (en) | 1991-12-05 | 1996-11-05 | Wallac Oy | Luminescent lanthanide chelates |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| AU685178B2 (en) | 1993-10-08 | 1998-01-15 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| PL185107B1 (pl) | 1995-06-21 | 2003-02-28 | Shionogi & Co | Bicykliczne związki aminowe, kompozycja farmaceutyczna i jej stosowanie |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| JP4120993B2 (ja) | 1996-12-12 | 2008-07-16 | 塩野義製薬株式会社 | ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤 |
| BR9714016A (pt) | 1996-12-13 | 2000-02-29 | Shionogi & Co | Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| ATE311200T1 (de) | 2000-04-12 | 2005-12-15 | Merck Frosst Canada Inc | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| AR035431A1 (es) | 2001-02-13 | 2004-05-26 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| EP1424335A4 (en) | 2001-09-07 | 2005-11-16 | Ono Pharmaceutical Co | INDOLE DERIVATIVES |
| EP1424325A4 (en) | 2001-09-07 | 2005-12-21 | Ono Pharmaceutical Co | INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
| WO2003097042A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Pgd2 receptor antagonist |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| DE10244810A1 (de) * | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| UA80871C2 (en) * | 2003-04-29 | 2007-11-12 | Pfizer Ltd | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
| EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| CA2534371A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| WO2008124505A2 (en) | 2007-04-05 | 2008-10-16 | Ironwood Pharmaceuticals,Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| MX2010012228A (es) * | 2008-05-10 | 2010-12-07 | Bayer Schering Pharma Ag | Estimuladores de sgc, activadores de sgc y combinaciones de los mismos para el tratamiento de la deficiencia auditiva. |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2565763B1 (en) | 2010-04-27 | 2018-04-18 | Nec Corporation | Information processing terminal and control method thereof |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| TWI532737B (zh) * | 2010-06-30 | 2016-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5878546B2 (ja) | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| US9284298B2 (en) * | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| CA2861804C (en) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| WO2014047111A1 (en) * | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2897953B8 (en) | 2012-09-19 | 2019-06-26 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| ES2911276T3 (es) | 2013-03-15 | 2022-05-18 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| JP2016540017A (ja) | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激物質 |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
-
2014
- 2014-03-14 ES ES19208775T patent/ES2911276T3/es active Active
- 2014-03-14 LT LTEP14718278.6T patent/LT2970243T/lt unknown
- 2014-03-14 PL PL19208775T patent/PL3660013T3/pl unknown
- 2014-03-14 LT LTEP19208775.7T patent/LT3660013T/lt unknown
- 2014-03-14 HR HRP20200276TT patent/HRP20200276T1/hr unknown
- 2014-03-14 PL PL14718278T patent/PL2970243T3/pl unknown
- 2014-03-14 ES ES14718278T patent/ES2774295T3/es active Active
- 2014-03-14 KR KR1020157029189A patent/KR102218771B1/ko active Active
- 2014-03-14 US US14/775,954 patent/US9481689B2/en active Active
- 2014-03-14 CN CN201811217841.2A patent/CN110016020B/zh active Active
- 2014-03-14 PT PT192087757T patent/PT3660013T/pt unknown
- 2014-03-14 MX MX2018014773A patent/MX384408B/es unknown
- 2014-03-14 HU HUE14718278A patent/HUE048543T2/hu unknown
- 2014-03-14 KR KR1020217004630A patent/KR102362835B1/ko active Active
- 2014-03-14 IL IL285564A patent/IL285564B2/en unknown
- 2014-03-14 CN CN201811217263.2A patent/CN109369635B/zh active Active
- 2014-03-14 AU AU2014227862A patent/AU2014227862C1/en active Active
- 2014-03-14 KR KR1020227004444A patent/KR102502937B1/ko active Active
- 2014-03-14 CN CN201810569286.3A patent/CN108912111B/zh active Active
- 2014-03-14 ME MEP-2020-40A patent/ME03664B/me unknown
- 2014-03-14 DK DK14718278.6T patent/DK2970243T3/da active
- 2014-03-14 SI SI201431948T patent/SI3660013T1/sl unknown
- 2014-03-14 EA EA201890641A patent/EA033168B1/ru unknown
- 2014-03-14 RS RS20220352A patent/RS63108B1/sr unknown
- 2014-03-14 EP EP21214096.6A patent/EP3998260B1/en active Active
- 2014-03-14 CN CN201480027900.3A patent/CN105408328B/zh active Active
- 2014-03-14 HR HRP20220376TT patent/HRP20220376T1/hr unknown
- 2014-03-14 PT PT147182786T patent/PT2970243T/pt unknown
- 2014-03-14 HU HUE19208775A patent/HUE059178T2/hu unknown
- 2014-03-14 SI SI201431503T patent/SI2970243T1/sl unknown
- 2014-03-14 CN CN201811216402.XA patent/CN109384778B/zh active Active
- 2014-03-14 EP EP19208775.7A patent/EP3660013B1/en active Active
- 2014-03-14 EP EP14718278.6A patent/EP2970243B1/en active Active
- 2014-03-14 EA EA201591743A patent/EA031746B1/ru unknown
- 2014-03-14 MX MX2015012473A patent/MX361208B/es active IP Right Grant
- 2014-03-14 CA CA2907111A patent/CA2907111C/en active Active
- 2014-03-14 RS RS20200218A patent/RS59981B1/sr unknown
- 2014-03-14 BR BR112015023349A patent/BR112015023349A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2016502769A patent/JP2016517432A/ja active Pending
- 2014-03-14 DK DK19208775.7T patent/DK3660013T3/da active
- 2014-03-14 ES ES21214096T patent/ES2966517T3/es active Active
- 2014-03-14 WO PCT/US2014/028370 patent/WO2014144100A2/en not_active Ceased
-
2015
- 2015-09-11 MX MX2021008281A patent/MX2021008281A/es unknown
- 2015-09-16 IL IL24164115A patent/IL241641B/en active IP Right Grant
-
2016
- 2016-07-21 US US15/215,628 patent/US9586937B2/en active Active
- 2016-08-24 US US15/245,697 patent/US10183021B2/en active Active
-
2017
- 2017-01-16 US US15/406,994 patent/US20170137439A1/en not_active Abandoned
- 2017-01-16 US US15/406,959 patent/US10517874B2/en active Active
- 2017-04-14 JP JP2017080301A patent/JP6267385B2/ja active Active
- 2017-04-14 JP JP2017080300A patent/JP6267384B2/ja active Active
-
2018
- 2018-10-12 JP JP2018193191A patent/JP6709000B2/ja active Active
- 2018-11-02 US US16/178,771 patent/US10639308B2/en active Active
-
2019
- 2019-05-22 AU AU2019203606A patent/AU2019203606B9/en active Active
- 2019-11-14 IL IL270646A patent/IL270646B/en active IP Right Grant
-
2020
- 2020-02-27 CY CY20201100188T patent/CY1122919T1/el unknown
- 2020-03-13 US US16/817,830 patent/US11207323B2/en active Active
- 2020-05-07 JP JP2020081703A patent/JP7072602B2/ja active Active
- 2020-12-23 IL IL279695A patent/IL279695B/en unknown
-
2021
- 2021-06-24 AU AU2021204292A patent/AU2021204292B2/en active Active
- 2021-12-20 US US17/556,213 patent/US20230106002A1/en not_active Abandoned
-
2022
- 2022-04-13 CY CY20221100280T patent/CY1125178T1/el unknown
-
2023
- 2023-04-04 AU AU2023202058A patent/AU2023202058B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| JP2019526582A5 (enExample) | ||
| HRP20200276T1 (hr) | Stimulatori sgc | |
| RU2013125480A (ru) | Стимуляторы sgc | |
| JP2016540017A5 (enExample) | ||
| JP2015503505A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2015508749A5 (enExample) | ||
| JP2016537389A5 (enExample) | ||
| HRP20150159T1 (hr) | Novi spojevi koji se vežu za fxr (nr1h4) i moduliraju njegovu aktivnost | |
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| JP2015529235A5 (enExample) | ||
| JP2017514855A5 (enExample) | ||
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| JP2015503504A5 (enExample) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2015506347A5 (enExample) | ||
| JP2016512505A5 (enExample) | ||
| TW202617707A (zh) | 一種結晶型ｃｓｆ－１ｒ抑制劑酸式鹽及其製備方法和應用 | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2013533318A5 (enExample) | ||
| RU2018131440A (ru) | Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания | |
| JP2017529389A5 (enExample) | ||
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| JP2018514535A5 (enExample) |